Literature DB >> 9582259

Effect of spinal cord injury on the permeability of the blood-brain and blood-spinal cord barriers to the neurotropin PACAP.

W A Banks1, A J Kastin, A Arimura.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) has been shown to be a potent neurotropin. Because PACAP crosses the blood-brain barrier (BBB) by peptide transport system (PTS)-6, it can exert its neurotropic effects even when given peripherally. Recent studies have shown that the activity of BBB transporters of peptides and regulatory proteins can be affected by pathophysiological events, including spinal cord injury. We, therefore, determined whether PTS-6 is affected by spinal cord injury. We found that radioactively iodinated PACAP was taken up by brain and by all regions of the spinal cord. PTS-6 activity was demonstrable in the brain and the cervical and thoracic regions of the spinal cord. Spinal cord transection had widespread and long-lasting effects throughout the CNS on PTS-6 activity. The most dramatic effect was an anatomically descending decrease of PTS-6 activity that began in the brain immediately after injury. Later, beginning on day 7 after injury, PTS-6 activity was increased throughout the CNS. These effects on PTS-6 were unrelated to the negligible disruption of barrier function by the injury. We conclude that spinal cord injury results in responses that are regionally and temporally unique to PTS-6 and could affect the delivery of blood-borne PACAP to the CNS. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9582259     DOI: 10.1006/exnr.1998.6786

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  9 in total

1.  Peptidergic mechanisms of hyperthermia-evoked convulsions in rats in early postnatal ontogenesis.

Authors:  N E Chepurnova; A A Ponomarenko; S A Chepurnov
Journal:  Neurosci Behav Physiol       Date:  2002 Sep-Oct

2.  Upregulation of tumor necrosis factor alpha transport across the blood-brain barrier after acute compressive spinal cord injury.

Authors:  W Pan; A J Kastin; R L Bell; R D Olson
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

3.  Transcellular routes of blood-brain barrier disruption.

Authors:  Michelle A Erickson; William A Banks
Journal:  Exp Biol Med (Maywood)       Date:  2022-03-04

Review 4.  Cytokine transport across the injured blood-spinal cord barrier.

Authors:  Weihong Pan; Abba J Kastin
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

5.  C-terminal amidation of PACAP-38 and PACAP-27 is dispensable for biological activity at the PAC1 receptor.

Authors:  Andrew C Emery; Ryan A Alvarez; Philip Abboud; Wenqin Xu; Craig D Westover; Maribeth V Eiden; Lee E Eiden
Journal:  Peptides       Date:  2016-03-11       Impact factor: 3.750

6.  Effect of controlled cortical impact on the passage of pituitary adenylate cyclase activating polypeptide (PACAP) across the blood-brain barrier.

Authors:  Elizabeth M Rhea; Kristin M Bullock; William A Banks
Journal:  Peptides       Date:  2017-10-28       Impact factor: 3.750

Review 7.  Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine.

Authors:  Faisal Mohammad Amin; Henrik Winther Schytz
Journal:  J Headache Pain       Date:  2018-05-21       Impact factor: 7.277

8.  Spike protein multiorgan tropism suppressed by antibodies targeting SARS-CoV-2.

Authors:  Molly Brady; Conor McQuaid; Alexander Solorzano; Angelique Johnson; Abigail Combs; Chethana Venkatraman; Akib Rahman; Hannah Leyva; Wing-Chi Edmund Kwok; Ronald W Wood; Rashid Deane
Journal:  Commun Biol       Date:  2021-11-22

9.  Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism.

Authors:  Christopher R Apostol; Kelsey Bernard; Parthasaradhireddy Tanguturi; Gabriella Molnar; Mitchell J Bartlett; Lajos Szabò; Chenxi Liu; J Bryce Ortiz; Maha Saber; Katherine R Giordano; Tabitha R F Green; James Melvin; Helena W Morrison; Lalitha Madhavan; Rachel K Rowe; John M Streicher; Michael L Heien; Torsten Falk; Robin Polt
Journal:  Front Drug Discov (Lausanne)       Date:  2022-01-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.